Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

HuidaGene Partners Use of CRISPR nuclease (hfCas12Max) with Synthego

publication date: May 29, 2024

Shanghai HuidaGene Therapeutics, a company that develops CRISPR-based genomic medicines, partnered its high-fidelity Cas12 CRISPR nuclease (hfCas12Max) with Synthego of Redwood City, CA. HuidaGene granted Synthego non-exclusive manufacturing and commercialization rights for the hfCas12Max nuclease and optimized gRNA for research. Synthego will also have the right to sublicense the nuclease for therapeutic use. Synthego offers novel CRISPR solutions for developing cell and gene therapies. The companies said the partnership reflects the clinical utility of hfCas12Max and complements Synthego's focus on advanced GMP manufacturing. Terms of the agreement were not disclosed. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital